ABSTRACT

Purpose

To describe endogenous endophthalmitis in the setting of Covid-19 pneumonia post recovery.

Methods

Retrospective review of five patients of endogenous endophthalmitis following Covid-19 disease done.

Results

All five cases had received systemic corticosteroid for a mean duration of 7 days during severe Covid-19 treatment. Decrease vision was presenting symptom between 1 and 31 days following Covid-19 recovery. All patients had presumed fungal endogenous endophthalmitis based on clinical profile. Four out of five patients subjected to pars plana vitrectomy had microbiologically proven aspergillus species endogenous endophthalmitis on vitreous fluid assessment; two cases each of aspergillus niger and aspergillus fumigates. Four eyes underwent pars plana vitrectomy with silicone oil injection had shown satisfactory anatomical outcome with control of the infection; however, no significant visual gain achieved.

Conclusion

We reported five cases of aspergillus endogenous endophthalmitis in Covid-19 recovered patients to document the likely presentation of this rising entity and avoid misdiagnosis.

中文翻译：

---

COVID-19 后康复患者的视网膜下曲霉菌脓肿——一个新出现的问题

摘要

目的

描述 Covid-19 肺炎康复后的内源性眼内炎。

方法

对 5 名 Covid-19 病后内源性眼内炎患者的回顾性研究。

结果

在严重的 Covid-19 治疗期间，所有 5 例病例均接受了平均持续 7 天的全身性皮质类固醇治疗。Covid-19 康复后 1 至 31 天出现视力下降症状。根据临床特征，所有患者均被推测为真菌性内源性眼内炎。五分之四接受睫状体玻璃体切除术的患者在玻璃体液评估中经微生物学证实为曲霉菌属内源性眼内炎；黑曲霉和熏曲霉各2例。4只眼接受硅油注射的睫状体平面玻璃体切除术，解剖学结果令人满意，感染得到控制；然而，没有取得显着的视觉增益。

结论

我们报告了 5 例 Covid-19 康复患者的曲霉菌内源性眼内炎病例，以记录这种上升实体的可能表现并避免误诊。